ROSE Zur Rose Group AG

EQS-News: The Zur Rose Group nominates three new board members

EQS Group-News: Zur Rose Group AG / Key word(s): Personnel
The Zur Rose Group nominates three new board members

15.04.2019 / 06:55


Press release

The Zur Rose Group nominates three new board members

The Zur Rose Group is nominating Tobias Hartmann, Dr. Christian Mielsch and Florian Seubert as new members of the Board of Directors and proposing them for election at the General Meeting of Shareholders to be held on 23 May 2019. The nomination is intended to add proven expertise in technology, trading and finance to the company's highest board.

As part of the positioning of the Zur Rose Group as a comprehensive, integrated healthcare platform and its associated further development as an e-commerce-oriented company, the Board of Directors has decided to propose to the Annual General Meeting that the Board of Directors be increased from six to seven members. In the view of the Board of Directors, the three candidates will ideally complement the Board. As already communicated, Dr. Heinz O. Baumgartner and Vanessa Frey are retiring from the Board of Directors.

Tobias Hartmann, CEO of Scout24 AG, has more than two decades of international management experience in the market launch, development and growth of businesses in the consumer products and (e-commerce) platform solutions sector. He has worked for both private and publicly listed companies in Europe and the USA. Dr. Christian Mielsch, Member of the Management Board and CFO of the REWE Group, is a proven expert, most notably in M&A and retail finance and controlling, after having held consecutive positions involving financial responsibility in groups operating on an international scale before joining REWE, among others at the Metro Group. As co-founder of the e-commerce company zooplus AG, Florian Seubert has broad entrepreneurial experience. He is regarded as an expert in e-commerce and in his current function as an independent professional investor and investment manager.

Prof. Stefan Feuerstein, Chairman of the Board of Directors of the Zur Rose Group, is delighted: "In Tobias Hartmann, Dr. Christian Mielsch and Florian Seubert we have three top-class business representatives who we can nominate to the Board of Directors of the Zur Rose Group, and who will contribute to the success of the company with their broad know-how and long-standing experience in management functions."

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: , phone: 9

Media contact
Lisa Lüthi, Head of Corporate Communications
Email: , phone: 4

Financial Calendar
17 April 2019 Q1/2019 Trading Update
23 May 2019 Annual General Meeting
21 August 2019 2019 Half-Year Results
23 October 2019 Q3/2019 Trading Update



Curriculum Vitae

Tobias Hartmann (46, German) has been CEO of Scout24 AG, Munich, since November 2018. Before joining Scout24 he was Board Member and President US of HelloFresh SE, Berlin and New York, the world's leading supplier of meal kits. Prior to that, he was President of US-based Radial Inc., a provider of omnichannel e-commerce and payment handling solutions, which was once part of eBay Inc. In addition, he was on the Management of Loyalty Partner GmbH and tasked with establishing "Payback" as a leading customer loyalty programme. Tobias Hartmann has a Bachelor of Arts (BA) in Economics from Clark University, Worcester (Massachusetts), USA, and a Master of Business Administration (MBA).

Dr. Christian Mielsch (56, German) has been a Board Member and CFO of the REWE Group, Cologne, since 2012. Prior to that, he held various executive positions in the Metro Group, including as CFO of Metro Cash&Carry International and most recently as COO Metro Cash&Carry Central East Europe. In 1997 he began his career with the Düsseldorf retail company as divisional head of controlling at Metro Cash&Carry International. Prior to that, he held executive roles at Bertelsmann AG, Munich, and at McKinsey&Comp, Düsseldorf. Christian Mielsch studied Physics and Business Administration in Dortmund and Hagen and earned a doctorate as Dr. rer. nat.

From 1999 to 2013, Florian Seubert (45, German) was co-founder and CFO of zooplus AG, Munich, which developed during his tenure from a start-up to an SDAX-listed European market leader which today has over EUR 1.6 billion in revenue and an active presence in more than 20 country markets. Prior to becoming an entrepreneur, Florian Seubert was employed at JPMorgan in London and New York in the Securities Division. Florian Seubert has a Masters degree (MA Oxon) in Philosophy, Politics and Economics from Oxford University, UK, and has been a partner and private investor at Maxburg Capital Partners, Munich, since 2013.

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management and actively promotes its positioning as a comprehensive, integrated cross-service healthcare platform. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.

The Zur Rose Group is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. The company employs over 1,300 people at various locations and generated a turnover of CHF 1,207 million in the 2018 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com



End of Corporate News


Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland
Phone: 4
Internet:
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 799479

 
End of News EQS Group News Service

799479  15.04.2019 

fncls.ssp?fn=show_t_gif&application_id=799479&application_name=news&site_id=research_pool
EN
15/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zur Rose Group AG

 PRESS RELEASE

DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the ...

DocMorris AG / Key word(s): Development of Sales DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter 21.01.2025 / 06:58 CET/CEST Frauenfeld, 21 January 2025 Press release DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter All business divisions contribute to revenue growth in 2024 OTC revenues increase by 6.7 per cent in 2024 New Rx customers grew fivefold and Rx revenue up 16.6 per cent in the fourth quarter of 2024 TeleClinic with profitable doubling of revenue in 2024 Cash position of CHF 95 million...

 PRESS RELEASE

DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im v...

DocMorris AG / Schlagwort(e): Umsatzentwicklung DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal 21.01.2025 / 06:58 CET/CEST Frauenfeld, 21. Januar 2025 Medienmitteilung DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal Alle Geschäftsbereiche tragen zum Umsatzwachstum 2024 bei OTC-Umsatz 2024 erhöht sich um 6.7 Prozent Rx-Neukunden verfünffacht und Rx-Umsatz plus 16.6 Prozent im vierten Quartal 2024 TeleClinic mit profitabler Umsatzverdoppelung in 2024 Cashbestand von CHF 95 Mio. per Ende 2024 DocM...

 PRESS RELEASE

DocMorris beschleunigt Rx-Wachstum

DocMorris AG / Schlagwort(e): Quartals-/Zwischenmitteilung DocMorris beschleunigt Rx-Wachstum 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15. Oktober 2024 Medienmitteilung DocMorris beschleunigt Rx-Wachstum Rx-Umsatzwachstum von 12.2 Prozent im dritten Quartal Beschleunigung auf über 25 Prozent in den letzten Wochen Starke Zunahme der Rx-Neukunden OTC-Wachstum von 1.9 Prozent Pablo Ros Gomez wird neuer CTO Schliessung des Logistikstandorts in Halle (DE) Das E-Rezept-Geschäft von DocMorris nimmt weiter Fahrt auf: Im dritten Quartal 2024 wuchs der Aussenumsatz mit versch...

 PRESS RELEASE

DocMorris accelerates Rx growth

DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15 October 2024 Press release DocMorris accelerates Rx growth Rx revenue growth of 12.2 per cent in the third quarter Acceleration to over 25 per cent in the last few weeks Strong increase in new Rx customers OTC growth of 1.9 per cent Pablo Ros Gomez becomes new CTO Closure of the logistics site in Halle (DE) DocMorris' e-prescription business continues to gain momentum: In the third quarter of 2024, external revenue of prescription med...

 PRESS RELEASE

DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukun...

DocMorris AG / Schlagwort(e): Quartals-/Zwischenmitteilung DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukunden, Marktanteil und Umsatz 11.07.2024 / 06:58 CET/CEST Frauenfeld, 11. Juli 2024 Medienmitteilung DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukunden, Marktanteil und Umsatz Verdreifachung der Rx-Neukundenzahl seit CardLink-Einführung Verdoppelung und kontinuierliche Steigerung des eRx-Marktanteils seit Januar 2024 17 Prozent Umsatzwachstum rezeptpflichtiger Medikamente (Rx) gegenüber Vorquartal Seit Mitte April ist de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch